BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32543362)

  • 1. Butterfly Structure: A Privileged Scaffold Targeting Tubulin-Colchicine Binding Site.
    Wang Y; Yao Y; Zhu HL; Duan Y
    Curr Top Med Chem; 2020; 20(17):1505-1508. PubMed ID: 32543362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site.
    Li L; Jiang S; Li X; Liu Y; Su J; Chen J
    Eur J Med Chem; 2018 May; 151():482-494. PubMed ID: 29649743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Novel Diarylamide
    Liu X; Pang XJ; Liu Y; Liu WB; Li YR; Yu GX; Zhang YB; Song J; Zhang SY
    Molecules; 2021 Jul; 26(13):. PubMed ID: 34279387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents.
    Duan Y; Liu W; Tian L; Mao Y; Song C
    Curr Top Med Chem; 2019; 19(15):1289-1304. PubMed ID: 31210108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site.
    Wu X; Wang Q; Li W
    Anticancer Agents Med Chem; 2016; 16(10):1325-38. PubMed ID: 26899186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures.
    Li W; Sun H; Xu S; Zhu Z; Xu J
    Future Med Chem; 2017 Oct; 9(15):1765-1794. PubMed ID: 28929799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding Site.
    Dong M; Liu F; Zhou H; Zhai S; Yan B
    Molecules; 2016 Oct; 21(10):. PubMed ID: 27754459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
    Wang Y; Zhang H; Gigant B; Yu Y; Wu Y; Chen X; Lai Q; Yang Z; Chen Q; Yang J
    FEBS J; 2016 Jan; 283(1):102-11. PubMed ID: 26462166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, Synthesis, and Biological Evaluation of 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazole Analogues as Potential Anticancer Agents Targeting Tubulin Colchicine Binding Site.
    Liu YN; Wang JJ; Ji YT; Zhao GD; Tang LQ; Zhang CM; Guo XL; Liu ZP
    J Med Chem; 2016 Jun; 59(11):5341-55. PubMed ID: 27172319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tubulin inhibitors: Discovery of a new scaffold targeting extra-binding residues within the colchicine site through anchoring substituents properly adapted to their pocket by a semi-flexible linker.
    Maklad RM; AbdelHafez EMN; Abdelhamid D; Aly OM
    Bioorg Chem; 2020 Jun; 99():103767. PubMed ID: 32325332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
    Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
    Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular interactions at the colchicine binding site in tubulin: An X-ray crystallography perspective.
    Wang J; Miller DD; Li W
    Drug Discov Today; 2022 Mar; 27(3):759-776. PubMed ID: 34890803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin.
    Bhattacharyya B; Panda D; Gupta S; Banerjee M
    Med Res Rev; 2008 Jan; 28(1):155-83. PubMed ID: 17464966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New indole-based chalconoids as tubulin-targeting antiproliferative agents.
    Mirzaei H; Shokrzadeh M; Modanloo M; Ziar A; Riazi GH; Emami S
    Bioorg Chem; 2017 Dec; 75():86-98. PubMed ID: 28922629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of a benzylidene derivative of 9(10H)-anthracenone in complex with tubulin provides a rationale for drug design.
    Cheng J; Wu Y; Wang Y; Wang C; Wang Y; Wu C; Zeng S; Yu Y; Chen Q
    Biochem Biophys Res Commun; 2018 Jan; 495(1):185-188. PubMed ID: 29102632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural insights into the design of indole derivatives as tubulin polymerization inhibitors.
    Li Y; Yang J; Niu L; Hu D; Li H; Chen L; Yu Y; Chen Q
    FEBS Lett; 2020 Jan; 594(1):199-204. PubMed ID: 31369682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discovery of novel indazole derivatives as tubulin colchicine site binding agents that displayed potent antitumor activity both in vitro and in vivo.
    Cui YJ; Ma CC; Zhang CM; Tang LQ; Liu ZP
    Eur J Med Chem; 2020 Feb; 187():111968. PubMed ID: 31865012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrostatic contributions to colchicine binding within tubulin isotypes.
    Huzil JT; Barakat K; Tuszynski JA
    Electromagn Biol Med; 2009; 28(4):355-64. PubMed ID: 20017626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interaction of the B-ring of colchicine with alpha-tubulin: a novel footprinting approach.
    Chaudhuri AR; Seetharamalu P; Schwarz PM; Hausheer FH; Ludueña RF
    J Mol Biol; 2000 Nov; 303(5):679-92. PubMed ID: 11061968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of pseudolaric acid B with the colchicine site of tubulin.
    Sarkar T; Nguyen TL; Su ZW; Hao J; Bai R; Gussio R; Qiu SX; Hamel E
    Biochem Pharmacol; 2012 Aug; 84(4):444-50. PubMed ID: 22634405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.